Lexicon completes subject enrolment for DPNP trial of LX9211 [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
The trial has enrolled 494 subjects, surpassing the initial target by approximately 20%. Top-line data is anticipated in the first quarter of next year. The double-blind, dose-ranging, randomised, parallel-group, open-label extension trial began in December last year and aims to enrol adult subjects with type 1 or type 2 diabetes who are suffering from moderate to severe DPNP. It is a placebo-controlled trial, with the primary endpoint being the decrease of the Average Daily Pain Score (ADPS) at eight weeks. Secondary endpoints include the evaluation of changes in burning pain and sleep interference due to pain. The trial design allows subjects to continue one stable-dose DPNP therapy, reflecting the real-world use of new DPNP drugs. Lexicon Pharmaceuticals chief medical officer and senior vice-president Craig Granowitz said: "We are pleased to have completed enrolment for the PROGRESS study of LX9211 in DPNP, a condition for which there is a significant need for new, non-o
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)GlobeNewswire
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) [Yahoo! Finance]Yahoo! Finance
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)GlobeNewswire
- Lexicon Pharmaceuticals to Participate in December Investor Conferences [Yahoo! Finance]Yahoo! Finance
LXRX
Earnings
- 11/12/24 - Miss
LXRX
Sec Filings
- 12/16/24 - Form 3
- 12/9/24 - Form SC
- 12/2/24 - Form 4
- LXRX's page on the SEC website